Investor Overview

Webcast ImageWebcast
AtriCure, Inc. at Piper Jaffray 28th Annual Healthcare Conference  (Replay)
11/30/16 at 11:30 a.m. ET
Webcast ImageWebcast
AtriCure, Inc. at Canaccord Genuity Medical Technologies & Diagnostics Forum (Replay)
11/17/16 at 2:00 p.m. ET
Webcast ImageWebcast
AtriCure, Inc. at Stifel 2016 Healthcare Conference (Replay)
11/15/16 at 9:30 a.m. ET

Corporate Profile

AtriCure is a medical device company providing innovative solutions designed to decrease the global Afib epidemic.

Stock Quote

ATRC (Common)
PriceChange% ChangeVolume
$18.55 + 0.281.53%268,998
Previous CloseToday's OpenIntraday HighIntraday Low
$18.27$18.34$18.99$17.97
Exchange: NASDAQ (US Dollar)
12/09/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Featured Reports

Date
10/27/16
Download Documentation Investor Presentation
08/08/16
Download Documentation Q2 2016 Earnings Call Transcript
04/18/16
Download Documentation 2015 Annual Report

All Recent News

DateTitle 
11/11/16AtriCure Names Sven Wehrwein to its Board of Directors
MASON, Ohio--(BUSINESS WIRE)--Nov. 11, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that Sven Wehrwein has been appointed to its Board of Directors. Mr. Wehrwein has been an independent financial consultant to emerging companies since 1999. He has more than 35 years of experience as an investment banker, chief financ... 
Printer Friendly Version
11/07/16AtriCure to Present at the Piper Jaffray 28th Annual Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--Nov. 7, 2016-- AtriCure, Inc. (Nasdaq:ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Piper Jaffray 28th Annual Healthcare Conference at the Lotte New York Palace Hotel in New York City on Wednesday, November 30, 2016. Management is scheduled to present at 11:30 a.m. Eastern Time. A live audio webcast... 
Printer Friendly Version
11/01/16AtriCure Announces Approval for the cryoICE™ Platform in Japan
Approval adds to the growing portfolio of AtriCure products now available in the Japanese market MASON, Ohio--(BUSINESS WIRE)--Nov. 1, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for its cryoICE™ platform and CRYO2 cryoablation ... 
Printer Friendly Version
10/27/16AtriCure Reports Third Quarter 2016 Financial Results
Revenue of $38.3 million – up 22.0% U.S. sales of $30.6 million – up 24.0% International sales of $7.8 million – up 14.9% MASON, Ohio--(BUSINESS WIRE)--Oct. 27, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced third quarter 2016 financial results. “We are pleased to report solid t... 
Printer Friendly Version
  More News >>

National Recent News

DateTitle 
11/11/16AtriCure Names Sven Wehrwein to its Board of Directors
MASON, Ohio--(BUSINESS WIRE)--Nov. 11, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that Sven Wehrwein has been appointed to its Board of Directors. Mr. Wehrwein has been an independent financial consultant to emerging companies since 1999. He has more than 35 years of experience as an investment banker, chief financ... 
Printer Friendly Version
11/07/16AtriCure to Present at the Piper Jaffray 28th Annual Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--Nov. 7, 2016-- AtriCure, Inc. (Nasdaq:ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Piper Jaffray 28th Annual Healthcare Conference at the Lotte New York Palace Hotel in New York City on Wednesday, November 30, 2016. Management is scheduled to present at 11:30 a.m. Eastern Time. A live audio webcast... 
Printer Friendly Version
10/27/16AtriCure Reports Third Quarter 2016 Financial Results
Revenue of $38.3 million – up 22.0% U.S. sales of $30.6 million – up 24.0% International sales of $7.8 million – up 14.9% MASON, Ohio--(BUSINESS WIRE)--Oct. 27, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced third quarter 2016 financial results. “We are pleased to report solid t... 
Printer Friendly Version
10/24/16AtriCure Announces Upcoming Investor Conference Schedule
MASON, Ohio--(BUSINESS WIRE)--Oct. 24, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Stifel Healthcare Conference at the Lotte New York Palace Hotel in New York City on Tuesday, November 15, 2016. Management is scheduled to present at 9:30 a.m. Eastern Time. A live audio webcast of the presentation may be access... 
Printer Friendly Version
  More National News >>

International Recent News

DateTitle 
11/01/16AtriCure Announces Approval for the cryoICE™ Platform in Japan
Approval adds to the growing portfolio of AtriCure products now available in the Japanese market MASON, Ohio--(BUSINESS WIRE)--Nov. 1, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for its cryoICE™ platform and CRYO2 cryoablation ... 
Printer Friendly Version
06/29/16AtriCure Receives CE Mark for the AtriClip® PRO2 Device
CE Mark brings the increased functionality of the AtriClip PRO2 device to the European market for use in managing the left atrial appendage; product was launched in the U.S. in April 2016 MASON, Ohio--(BUSINESS WIRE)--Jun. 29, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has received CE Mark for the AtriClip PRO2 Left ... 
Printer Friendly Version
01/19/16AtriCure Announces Approval for the AtriClip in Japan
Approval opens up a new market for the most widely implanted left atrial appendage occlusion device in the world WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 19, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for its AtriClip™ product... 
Printer Friendly Version
10/01/13In the Fight Against Atrial Fibrillation, AtriCure Launches Maze IV Training Program in Europe
AMSTERDAM, Netherlands--(BUSINESS WIRE)--Oct. 1, 2013-- AtriCure, Inc. (Nasdaq: ATRC), is partnering with leading atrial fibrillation (Afib) centers and thought leaders across Europe to provide best-in-class training on surgical ablation. The launch of an international Maze IV Training program will take place on October 1 in Germany at Sana Stuttgart Cardiac Surgery Center, one of six initial European hospitals selected to participate in th... 
Printer Friendly Version
  More International News >>

Company Calendar

There are currently no events scheduled.
  More Events >>

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.